Plain-English translation of NCT02074839 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new medication called to see if it can help people with advanced blood cancers (like acute myeloid leukemia) or related conditions that have a specific genetic change called an IDH1 mutation. The trial will first figure out the right dose of the medication by slowly increasing it in small groups of patients, then test that dose in larger groups to see how safe and effective the treatment is.
Some blood cancers have a genetic mutation that may be targetable with new treatments, but there are still limited options for patients with these mutations—especially those whose cancer has come back or stopped responding to standard therapy. This study is exploring whether this medication could offer a new hope for these patients.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth every day as part of a 28-day treatment cycle. You'll need to visit the study center regularly for blood tests, bone marrow biopsies, and urine samples so the researchers can monitor how the medication is working and check for any side effects. You will continue treatment until your cancer progresses or you experience side effects that are too serious to continue.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
United States